drugset / Trial / NCT00864734
A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions
RandomizedCrossoverOpen-label
Summary
The purpose of this study is to compare the relative bioavailability of 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets by Purepac Pharmaceutical Co. with that of 5 mg/500 mg CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult volunteers under non-fasting conditions.
Timeline
- Start
- 2002-11
- Primary completion
- 2002-11
- Completion
- 2002-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glyburide | Small molecule | 5 mg | Oral |
| Comparator | Metformin | Small molecule | 500 mg | Oral |
Indications
No indication recorded.